Therapeutic glucocorticoids mechanisms of actions in rheumatic diseases

Raza, Karim; Hardy, Rowan; Cooper, Mark S.

DOI:

[10.1038/s41584-020-0371-y](https://doi.org/10.1038/s41584-020-0371-y)

<https://www.nature.com/articles/s41584-020-0371-y#article-info>

License:

Other (please specify with Rights Statement)

Document Version

Peer reviewed version

Citation for published version (Harvard):

Raza, K, Hardy, R & Cooper, MS 2020, 'Therapeutic glucocorticoids mechanisms of actions in rheumatic diseases', *Nature Reviews Rheumatology*, vol. 16, no. 3, pp. 133-144. <https://doi.org/10.1038/s41584-020-0371-y>, <https://doi.org/https://www.nature.com/articles/s41584-020-0371-y#article-info>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Subject to Springer Nature re-use terms: <https://www.nature.com/nature-research/editorial-policies/self-archiving-and-license-to-publish#terms-for-use>

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases

[Au: Shortened title OK? (as the character limit for titles is 90 characters, including spaces). Also changed to "rheumatic" to make the rheumatology aspect more clear]

Comment [MC1]: This is ok.

Rowan S. Hardy¹, Karim Raza¹ and Mark S. Cooper² [Au: Author names OK - with the order and abbreviations as you would like to them appear on the article?]

Comment [MC2]: Yes all ok and accurate

¹University of Birmingham, Birmingham, UK

²ANZAC Research Institute, University of Sydney, Sydney, Australia

[Au: Affiliations correct?]

Comment [MC3]: Correct

Abstract

Therapeutic glucocorticoids have been widely used in rheumatic diseases since they became available over 60 years ago. Despite the advent of more specific biologic therapies, a notable proportion of individuals with chronic rheumatic diseases continue to be treated with these drugs. Glucocorticoids are powerful, broad spectrum anti-inflammatory agents but their use is complicated by an equally broad range of adverse effects. The specific cellular mechanisms by which glucocorticoids have their therapeutic action have been difficult to identify, and attempts to develop more selective drugs on the basis of the action of [Au: OK? is this what you meant? Or the structure?] glucocorticoids have proven difficult. The actions of glucocorticoid seem to be highly cell type and context dependent. Despite emerging data on the effect of tissue-specific manipulation of glucocorticoid receptors in rodent [Au: rodent meaning mouse?] models of inflammation, the cell types and intracellular targets of glucocorticoids in rheumatic diseases have not been fully identified. Although showing some signs of decline, the use of systemic glucocorticoids in rheumatology is likely to continue to be widespread and careful consideration is required by rheumatologists to balance the beneficial effects and deleterious effects of these agents [Au: OK?].

Comment [MC4]: This is ok. The structure is not important, it is the action that is relevant

Comment [MC5]: Yes. All the models have used mice rather than rats. I would be happy with the term mouse instead of rodent.

Comment [MC6]: Yes, ok with me.

[Au: For your information, H1 and H2 refer to the level of heading and will be removed before proofs are made. H1 subheadings can have max 38 characters including spaces. H2 subheadings can have a max 80 characters including spaces. Subheads have been edited to fit these limits, where indicated]

[H1] Introduction

The introduction of glucocorticoids and their notable effects in the treatment of patients with rheumatoid arthritis (RA) led to the award of the Nobel Prize for Physiology or Medicine in 1950¹. Subsequently, systemic glucocorticoid therapy has been employed in a range of rheumatic diseases. For many of these conditions, the evidence for glucocorticoid therapy remains based on clinical experience rather than rigorous clinical trials. Despite the introduction of biologic drugs, which have a much greater specificity for components of the immune system than glucocorticoids, systemic glucocorticoid therapy continues to be widely used².

In the general population, ~1% of individuals are treated with oral glucocorticoids on a long-term basis, and this figure rises to around 3% in elderly individuals^{3,4}. In individuals with RA, oral glucocorticoid usage continues to be widespread, although is potentially declining [Au: OK?]². For some conditions (such as systemic vasculitis, systemic lupus erythematosus and polymyalgia rheumatica), the use of glucocorticoids for long periods of time remains an important part of current treatment approaches.

The adverse effects of prolonged glucocorticoid therapy are well established and extremely common⁵. Glucocorticoids have effects on [Au: OK? Is this what you meant?] almost all tissues and bodily systems (the selected effects of glucocorticoids are represented in supplementary figure 1). Adverse effects of particular medical importance include osteoporosis and fracture, glucose intolerance and diabetes, central obesity, [Au: What do you mean by central obesity?] muscle wasting, increased risk of infection, depression and cataracts. [Au: Please reference this statement.] The effect of glucocorticoids on bone is related to the dose and duration of therapy but treatment durations beyond 3 months are associated with a 30% increase in overall fracture risk and at least a doubled risk of vertebral fracture⁶. The risk of developing diabetes is doubled in patients with RA taking prednisolone doses of 7.5mg or above⁵. Although adverse effects on bone can be mitigated pharmacologically [Au: With what therapies?], the effects on other tissues such as muscle wasting, skin thinning, obesity and increased risk of diabetes have no specific treatment. Patient perceptions of adverse effects often differ from those of their treating clinician^{8,9} with features such as weight gain and insomnia rated very important by patients whereas clinicians focussed on features such as diabetes and infection risk (considered less important by patients). [Au: Could you elaborate a little more (to clarify the relevance to glucocorticoid therapy specifically?).]

Comment [MC7]: Yes, this is what the data shows.

Comment [MC8]: Typo. Probably from the original version

Comment [MC9]: Yes this is ok.

Comment [MC10]: This is a common term in endocrinology but maybe not rheumatology. It refers to the accumulation of fat in the abdomen (and neck) rather than in the limbs. 'Visceral' obesity would be a synonym. Alternatively 'accumulation of fat in the abdomen' would be accurate.

Comment [MC11]: Much of this literature is classical but I would suggest: Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, Dasgupta B, Dixon WG, Geenen R, Huizinga TW, Kent A, de Thurah AL, Listing J, Mariette X, Ray DW, Scherer HU, Seror R, Spies CM, Tarp S, Wiek D, Winthrop KL, Buttgeit F. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. *Ann Rheum Dis*. 2016 Jun;75(6):952-7.

Comment [MC12]: This is discussed later but if needed the phrase 'with bisphosphonates or denosumab therapy' could be added.

Comment [MC13]: Attempted to do so.

Despite their widespread use over many decades the mechanisms by which glucocorticoids have their desired anti-inflammatory effects remain unclear. Many cell types and cellular pathways have been proposed as the key targets for these effects. Experimental evidence suggests that there is likely to be a diversity of cell types and pathways involved and these targets are likely to differ between different diseases treated. An improved understanding of these targets in specific disease states opens up the potential to design novel therapeutics that retain anti-inflammatory effects with less risk of adverse consequences.

[Au: So far you have introduced the use of glucocorticoids and their adverse effects, but haven't mentioned anything about mechanisms of action (until the paragraph below, describing what this Review will cover). Perhaps you could have a short paragraph here to outline the outstanding questions surrounding mechanisms of action of glucocorticoids and why understanding these mechanisms is useful (to help introduce the precise of this Review)]

Comment [MC14]: Completely agree. Paragraph added.

In this Review, we summarise the current understanding of the basis by which glucocorticoids have therapeutic effects in inflammatory, and in particular rheumatic, diseases. We consider the pharmacological properties that enable glucocorticoids to have useful effects in a wide range of conditions and the probable cellular targets of these actions. We also consider the molecular mechanisms underlying the adverse effects of glucocorticoids and assess the prospects for developing novel therapeutics that retain beneficial properties with reduced risks of adverse effects.

[H1] Glucocorticoids and their receptors [Au: OK?]

Comment [MC15]: Yes ok

Cortisol (referred to as hydrocortisone when used as a therapeutic) is the main endogenous glucocorticoid in humans. Cortisol secretion is essential to life **[Au: Is it possible to reference this statement?]**. This steroid hormone is released in a pronounced circadian rhythm (high in the morning before waking and very low around midnight) and its synthesis is considerably upregulated during states of stress. Cortisol is synthesised in the adrenal cortex from cholesterol and retains the cyclopentanoperhydrophenanthrene 'steroid' backbone structure. The synthetic glucocorticoids most commonly used to treat systemic inflammation in rheumatology (prednisolone, methylprednisolone and dexamethasone) are very similar in structure to cortisol, with only relatively modest modifications (figure 1) **[Au: OK?]**. These changes variously reduce enzymatic breakdown of the molecule to increase the ability of the steroid to bind to the glucocorticoid receptor **[Au: our journal style is to avoid 2-letter abbreviations (with some rare exceptions), and so I have removed the abbreviation GR throughout (unless referring to particular isoforms) OK?]**, and reduce or eliminate the intrinsic mineralocorticoid (salt retaining) activity. **[Au: Is there a reference you can provide for this background information on glucocorticoids?]**

Comment [MC16]: This is tricky. Addison described this condition in 1855 and it was well known from then on that if the adrenal glands failed death was inevitable. I could propose one of my previous references but this is quite general (and I'm aware that I've quoted my work in other areas already). The reference would be: Cooper MS1, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 Feb 20;348(8):727-34.

Comment [MC17]: Yes ok

Comment [MC18]: Yes ok

Comment [MC19]: I would suggest ref: Fuller PJ, Lim-Tio SS, Brennan FE. Specificity in mineralocorticoid versus glucocorticoid action. Kidney Int. 2000 Apr;57(4):1256-64.

[Au: Paragraph break OK here?] Endogenous glucocorticoids can bind to the glucocorticoid receptor (encoded by *NR3C1*) and the mineralocorticoid receptor [Au: encoded by? (to match the previous statement?)]. The glucocorticoid receptor is expressed in most cells within the body and is thought to mediate most of the anti-inflammatory and negative consequences of therapeutic glucocorticoids. The glucocorticoid receptor contains various structural domains important for ligand binding, nuclear localisation, DNA binding and activation functions¹⁰. The un-bound glucocorticoid receptor is found within the cytoplasm but is transported to the nucleus after binding of the receptor by glucocorticoid. The molecular actions arising from the glucocorticoid-bound glucocorticoid receptor are discussed in a later section [Au: OK?].

Comment [MC20]: Yes ok

Comment [MC21]: Encoded by NR3C2. Agree should be added

[Au: Paragraph break OK here?] The mineralocorticoid receptor is expressed primarily in cells that regulate salt and water balance such as the distal tubule of the kidney, the salivary and sweat glands and the colonic epithelium. Even though glucocorticoids such as cortisol and prednisolone have an affinity for the mineralocorticoid receptor, the interaction between these glucocorticoids and the mineralocorticoid receptor is prevented by the presence of an enzyme (corticosteroid 11 β -dehydrogenase isozyme 2 [Au: OK?] (11 β HSD2)); this enzyme inactivates these glucocorticoids [Au: these glucocorticoids specifically, or glucocorticoids in general?] in mineralocorticoid-sensitive cells¹¹. Glucocorticoids such as dexamethasone and triamcinolone do not bind the mineralocorticoid receptor and thus have no mineralocorticoid activity.

Comment [MC22]: Yes ok

Comment [MC23]: Yes ok

Comment [MC24]: I don't think this is ok. I have never seen this terminology in the medical literature or used it myself. This might be the term used by pure chemists (and Wikipedia!) but would prefer to stick with 11b-hydroxysteroid dehydrogenase type 2.

Comment [MC25]: These glucocorticoids is correct. The enzyme is selective for certain glucocorticoids so 'glucocorticoids' would be incorrect.

Comment [MC26]: Yes ok

[H1] Pharmacokinetics [Au: Shortened title (to fit character limits) OK?]

A fundamental structural property of therapeutic glucocorticoids is that they can pass through biological membranes to access intracellular receptors (figure 2). Glucocorticoids such as prednisone and prednisolone are efficiently absorbed through the gastrointestinal tract. Although poorly soluble in water owing to their lipophilic nature, glucocorticoids can be carried effectively in the circulation through their association with plasma proteins (primarily globulin and albumin [Au: OK?]). Orally or intravenously [Au: OK?] administered glucocorticoids can thus penetrate most tissues. Coupled with the almost universal distribution of glucocorticoid receptors within tissues, this high degree of penetration means that glucocorticoid therapy can target cells that mediate inflammation at a systemic level. This high bioavailability, however, comes at the price of considerable 'off target' exposure of tissues unrelated to the condition being treated. Some therapeutic glucocorticoids, such as cortisone and prednisone, lack intrinsic glucocorticoid receptor binding activity but when given orally [Au: why orally and not intravenously?] are converted to their active counterparts, cortisol and prednisolone, by 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1), an enzyme that is highly expressed in the liver (figure 2). Expression of 11 β -HSD1 in various stromal and immune cells can also amplify the actions of

Comment [MC27]: No. There is a specific type of 'globulin' than has high affinity for cortisol. It is termed 'corticosteroid binding globulin' so the phrase such be 'primarily corticosteroid binding globulin and albumin'

Comment [MC28]: Yes ok

Comment [MC29]: Cortisone and prednisone are only available in oral formulations. The key point here is that these can be given orally because they are converted to active forms on first pass through the liver (most oral drugs have to go through the liver before getting into the circulation). The sentence could be changed to include the phrase 'by first pass metabolism in the liver' since 'first pass metabolism is the technical term for this phenomena.

these glucocorticoids locally through conversion of these glucocorticoids from their inactive to their active forms^{12,13}.

The pharmacokinetic properties of glucocorticoids have been successfully modified to improve their therapeutic properties. The development of depot injections for joint and muscle injection has proven to be highly successful¹⁴. These depot injections are formulated such that the glucocorticoid is released at a much slower rate than typical glucocorticoid preparations. Another approach to improving glucocorticoid effectiveness through changes in their pharmacokinetics is the development of timed release preparations of glucocorticoids designed to mimic the circadian rhythm of cortisol release¹⁵. A formulation of prednisone has been developed that involves drug encapsulation. The drug is taken at night and the tablet releases prednisone ~4 hours after ingestion (that is, at approximately 2am if given at 10pm, thus mimicking the pattern of release of endogenous glucocorticoids). The timed approach seems to particularly benefit the early morning stiffness that occurs in RA¹⁶. Furthermore, this treatment approach has the potential to minimise the adverse metabolic effects of glucocorticoids that seem to be greater when administered at times when the normal circadian levels of cortisol should be low^{17,18}. In addition to the overall circadian rhythm, cortisol synthesis also follows an ultradian (minute to minute) rhythm. In human studies, the pattern of cortisol exposure seems important in determining the cognitive and emotional response to glucocorticoids¹⁹. Any such patterning will be absent during treatment with therapeutic glucocorticoids.

Considerable scope remains to further develop glucocorticoid-based therapies on the basis of manipulation of their pharmacokinetic properties such that these agents more selectively target specific tissues of interest. Examples of new strategies include the development and clinical evaluation of novel liposomal-based or nanoparticle-based treatments^{20,21}. In these preparations, glucocorticoids are attached to or incorporated within molecules that can be selectively taken up by specific cell types such as macrophages or that have better penetration [Au: Can I just check you don't mean better targeting to sites of inflammation? Or retention in site of inflammation? Or do you actually mean that have better penetrate into these sites?] at sites of inflammation. One study in a mouse model of arthritis showed the feasibility of loading glucocorticoids into a hydrogel that was sensitive to breakdown by enzymes released into the joint during inflammation²². After injection into the joint, this hydrogel–glucocorticoid complex reduced arthritis whereas the equivalent dose of free glucocorticoid did not, presumably because free glucocorticoid was rapidly lost from the joint. Although these strategies offer new opportunities for local and systemic treatments, they are likely to only fulfil their potential when targeted to the cells that directly mediate the beneficial effects of glucocorticoids [Au: OK?].

[H1] Mechanisms of action

Comment [MC30]: Better penetration is what we were getting at. Liposomes are large structures that cannot escape the circulation except where there is a breakdown of the vascular endothelium. Such a breakdown occurs at sites of inflammation. I agree that the sentence is a bit ambiguous as various approaches are used to try to get selectively greater action of glucocorticoids at specific tissues. None of them however involve retention.

Comment [MC31]: Yes ok

[H2] Glucocorticoid– glucocorticoid receptor interactions [Au: OK?]

Comment [MC32]: Yes ok

The majority of the therapeutic actions of glucocorticoids are thought to occur through interaction of glucocorticoids with the glucocorticoid receptor. ~~It is now clear—recent years~~

[Au: We prefer to avoid the word “recent” as it can be construed by different readers differently. What time frame are you referring to here? The last few years? The last decade?] ~~it has become clear~~ that the glucocorticoid receptor can have a variety of forms

Comment [MC33]: In light of this point I have changed the text. There are two different aspects to the isoform issue with different time frames so it would be confusing to specify a time frame.

[Au: OK?], which can influence glucocorticoid signalling. The complexity of the mechanism of action of the glucocorticoid receptor [Au: Is this what you meant?] is still being clarified

Comment [MC34]: Yes ok.

and a diverse array of glucocorticoid receptor isoforms (such as splice variants and isoforms with different translational start sites) can be present and differ between different tissues and between cells within the same tissue [Au: OK?] ²³. From the single *NR3C1* gene locus,

Comment [MC35]: Yes ok

two main transcriptional variants of the glucocorticoid receptor have been identified (termed GR α and GR β [Au: OK?]) ^{24, 25} (figure 3a). GR α is the primary transcript in most cells

Comment [MC36]: Yes ok

and contains all the domains required for glucocorticoid receptor signalling. The GR β transcript lacks the ability to bind endogenous glucocorticoids and is produced at a lower rate in most cells [Au: lower than what? Meaning lower than the GR α isoform?] but in

Comment [MC38]: Yes the GR α isoform

certain contexts production can be upregulated. In vitro studies suggest that GR β can have a dominant negative action on GR α through the formation of GR α –GR β heterodimers or GR β –GR β homodimers rather than GR α –GR α homodimers. A function for GR β in the development of resistance to glucocorticoid therapy in the clinical setting has been proposed ^{25, 26}. Although these studies are intriguing, a concrete link between GR β and rheumatic disease pathophysiology or response to therapeutic glucocorticoids has yet to be established.

Additional glucocorticoid receptor diversity arises from variation in glucocorticoid receptor isoform protein translation. At least 8 translational variants can be produced from the GR α transcript (termed GRA, GRB, GRC1, GRC2, GRC3, GRD1, GRD2 and GRD3). Importantly, these glucocorticoid receptor variants seem to differ in their ability to regulate gene expression ^{27,28}. Although GRA is the classical glucocorticoid receptor isoform that has been extensively studied, and is the isoform discussed almost exclusively below, the other protein isoforms can also be expressed at notable levels and this expression considerably varies between tissues [Au: OK?]. The glucocorticoid receptor isoforms can undergo a range of post-translational modifications including phosphorylation, acetylation, sumoylation and ubiquitination, which also influence the function of the glucocorticoid receptor ²⁹⁻³¹. The implications of translational isoforms and post-translational modifications of the glucocorticoid receptor in rheumatic diseases has not been examined, although a role for translational isoforms has been identified in the immune response to lipopolysaccharide in mice ²⁷.

Comment [MC39]: Yes ok

[H2] Glucocorticoid receptor signalling

The mechanisms by which glucocorticoid receptor complexes function are complex and still poorly understood. Although many variations of glucocorticoid receptor signalling mechanisms exist, these mechanisms can be broadly divided into transactivation and transrepression (Figure 3b). In transactivation, direct binding of the glucocorticoid receptor to specific DNA sequences, referred to as glucocorticoid response elements (GREs), causes an increase in gene transcription; this process generally occurs with glucocorticoid receptor dimers [Au: OK?]. In transrepression, monomeric glucocorticoid receptor 'tether' to specific factors in such a way that they cannot bind to DNA, interfering with downstream proinflammatory signalling pathways [Au: OK?]. As such, gene transcription is reduced without the glucocorticoid receptor directly interacting with the DNA. The term transrepression is also used for an additional mechanism in which glucocorticoid receptor homodimers bind to DNA GREs (so called negative GREs) such that gene transcription is inhibited [Au: Is this non-classical transrepression, as later you refer to "classical negative GREs" and "classical GREs". Or later, when you refer to "classical negative GREs", are you simply referring to all negative GREs?]. Other, less well characterised mechanisms by which glucocorticoids can signal include the release of chaperone proteins during binding of the glucocorticoid to the glucocorticoid receptor and through binding of glucocorticoids to cell membrane-associated glucocorticoid receptors^{32, 33}. A schematic overview of some of the ways in which the glucocorticoid receptor can function at a cellular level is outlined in figure 4. [Au: I moved this sentence down from the start of the paragraph so that figure 3 could be discussed fully before figure 4 is mentioned]

The classical view of glucocorticoid receptor signalling was that the metabolic actions of glucocorticoids (such as those leading to induction of hepatic gluconeogenetic enzymes) were primarily mediated via transactivation through binding of glucocorticoid receptor homodimers to the promoter regions of target genes. By contrast, the anti-inflammatory actions of glucocorticoids were thought to be caused by transrepressive interactions of monomeric glucocorticoid receptors with components of proinflammatory signalling pathways (most importantly NF-κB and AP-1) in ways not generally involving DNA binding, such that these pathways were suppressed. This model of glucocorticoid receptor signalling led to the concept that glucocorticoid-like molecules could be developed with reduced transactivation potential (and thus reduced adverse effects) but with retained or increased transrepression activity. This class of drugs has been labelled selective glucocorticoid receptor agonists (SEGRAs) or 'dissociated' glucocorticoid agonists. [Au: Please provide references for your description of this concept and class of drugs] Although providing a framework for commercial drug development, a range of experimental findings have shown that this concept has limitations. For example it is now established that some important anti-inflammatory genes such as *DUSP1*, *SPHK1* and *ANXA1* [Au: OK? Are you referring to genes in mice or humans here?] rely on classical transactivation [Au: What do you mean by "classical transactivation" (i.e. what would be non-classical transactivation)? I'm not sure

Comment [MC40]: Yes ok

Comment [MC41]: Yes ok

Comment [MC42]: noted

Comment [MC43]: A recent review is: Cooper MS, Zhou H, Seibel MJ. Selective glucocorticoid receptor agonists: glucocorticoid therapy with no regrets? J Bone Miner Res. 2012 Nov;27(11):2238-41. doi: 10.1002/jbmr.1753.

Comment [MC44]: These would be mouse studies

Comment [MC45]: I suggest removing the term classical as it is too confusing

257 **this has been introduced)** for glucocorticoid-mediated transcription **[Au: OK?]**³⁴⁻³⁶. Mice
 258 have been generated that have a targeted mutation of the glucocorticoid receptor such that
 259 the glucocorticoid receptor retains ligand-binding and DNA-binding capacity but has a
 260 reduced ability to form homodimers and thus transactivate gene promoters **[Au: This**
 261 **sentence was a little long so I've split into two, OK?]**. These mice, known as GR^{dim/dim} mice
 262 **[Au: OK?]**, have been used to examine the probable contribution that transactivation and
 263 transrepression make to the actions of glucocorticoids³⁷. GR^{dim/dim} mice were less
 264 responsive **[Au: meaning less responsive than wild-type mice?]** to the protective effects of
 265 glucocorticoid therapy during experimental sepsis indicating a protective role for
 266 glucocorticoid receptor transactivation in systemic inflammatory illness³⁸. Additionally,
 267 glucocorticoids still have detrimental effects on the bones of dimerization-deficient mice
 268 **[Au: Still referring to 'dim-dim' mice?]**, suggesting that the adverse effects on bone are
 269 mediated through transrepression³⁹.

270 Our understanding of the complexity of glucocorticoid receptor signalling has increased
 271 substantially with the advent of techniques that enable examination of in vivo glucocorticoid
 272 receptor binding across the whole genome. These techniques surprisingly show that the
 273 majority of glucocorticoid receptor DNA binding sites are not within ~~classical-predicted~~ gene
 274 promoters and that monomeric glucocorticoid receptors commonly bind to DNA in
 275 association with other transcription factors; furthermore, many of these responses are
 276 through binding of ~~non-classical~~ negative GREs with structures unlike previously described
 277 negative GREs **[Au: As mentioned above, could you clarify what you mean by "non-**
 278 **classical" here (i.e. what would be a classical negative GRE"?)]**⁴⁰. During treatment with
 279 pharmacological levels of glucocorticoids **[Au: meaning that the affects you describe in the**
 280 **previous sentence are of non-pharmacological (/lower) levels of glucocorticoids?]**, there
 281 seems to be a shift from binding to these unexpected GREs **[Au: from what?]** to increased
 282 binding ~~use of expected classical~~ GREs by glucocorticoid receptor homodimers⁴¹. The ability
 283 of glucocorticoid receptors to bind to specific areas of DNA varies considerably between cell
 284 types and even within the cell type, depending on the developmental stage and chromatin
 285 organisation of the cell⁴². For example, in cells of the monocyte lineage, glucocorticoid
 286 treatment affects the expression of more mRNAs in monocytes than in differentiated
 287 macrophages⁴³. Of the mRNAs affected in monocytes, the majority are related to cell
 288 differentiation. This finding is perhaps not a surprise given that the glucocorticoid receptor
 289 has to coordinate between determining cell lineage (glucocorticoids being important for the
 290 differentiation of many cell types) and regulating acute metabolic and stress responses **[Au:**
 291 **OK? Is this what you meant?]**.

292 Research in this area has been complicated by a reliance on experiments that involve
 293 cultured cells of mouse origin or transformed human cell lines. However, current studies are
 294 attempting to use primary cells isolated from humans, which should provide data that is
 295 generalizable and applicability to the clinical situation **[Au: OK?]**⁴⁴.

Comment [MC46]: Yes ok

Comment [MC47]: Yes ok

Comment [MC48]: Yes ok

Comment [MC49]: Yes, than wild type mice

Comment [MC50]: Yes these are the 'dim/dim' mice

Comment [MC51]: Yes. It might be made clear clearer by saying 'with higher levels of glucocorticoids in the pharmacological range'

Comment [MC52]: Yes it is

Comment [MC53]: Yes ok

[H2] Cellular targets of glucocorticoid signalling

This diversity of genomic targeting between cells is also paralleled by a diversity of transcriptional responses in various cell types. Glucocorticoids can affect the expression levels of up to 20% of all genes in immune cells⁴⁵. However, the number of genes affected differs considerably between cell types. In 2019, one study examined the glucocorticoid-induced changes in the transcriptome of various human primary cells (that is, monocytes, CD4 T cells, B cells, neutrophils, fibroblasts, myoblasts, preadipocytes, osteoblasts and endothelial cells). The cells were treated with therapeutic levels of glucocorticoids for between 2 and 6 hours⁴⁴. Notably, only a small number of genes were influenced by glucocorticoids in the same way across the different cell types. By contrast, each lineage had a distinct expression profile that only partially overlapped with the other cell types examined. This finding suggests that identifying some of the critical anti-inflammatory actions of glucocorticoids on specific cell types might lead to the development of more selectively targeted medications [Au: OK?]. However, these results also imply that therapeutic glucocorticoids in clinical practice target a range of cell types and cellular targets such that determining the exact mechanism by which glucocorticoids have beneficial effects, and testing these effects [Au: OK? Is this what you meant? Or else, this what (i.e. “this” requires a noun)] in adequately powered clinical trials, might prove extremely difficult.

Attempts to identify the exact target cells (for example, T cells, macrophages, dendritic cells and stromal cells [Au: Are these examples of target cells, or examples of potential target cells?]) of glucocorticoids in various rheumatic diseases has proven difficult. Even for cells that have been implicated in mediating glucocorticoid effects, identifying the specific cellular targets [Au: meaning molecular targets?] and/or consequences in these cells have proven difficult to dissect. In various contexts glucocorticoids have possible anti-inflammatory effects that can be mediated through changes in cellular proliferation, survival or differentiation, reduced expression of inflammatory mediators or increased expression of anti-inflammatory factors. Specific cellular factors, including nuclear factor- κ B (NF- κ B), AP-1, annexins, dual-specific phosphatases, glucocorticoid-induced leucine zipper and microRNAs, are considered important glucocorticoid targets in a variety of cell types⁴⁶. None of these factors have proven to be a dominant mechanism by which glucocorticoids exert their anti-inflammatory action. Selected examples of molecular pathways and processes thought to be important targets of glucocorticoid actions in specific tissues are highlighted in Table 1.

[H2] Insights from mouse models

Comment [MC54]: Yes ok

Comment [MC55]: Yes exactly what is meant

Comment [MC56]: These are examples of potential targets. The actual targets are not known

Comment [MC57]: Yes molecular is better

Additional insights into the specific targets of glucocorticoids in inflammatory arthritis have come from genetically modified mice that have targeted alterations of glucocorticoid receptor expression or signalling capacity⁴⁷. These studies (summarised in Table 2) have examined the critical target cells for therapeutic glucocorticoids in mouse [Au: OK?] models of acute and chronic polyarthritis. These inflammatory models include adjuvant-induced arthritis (AIA) and serum transfer induced arthritis (STIA). One study examined the effect of glucocorticoid receptor deletion in various cell types on the ability of glucocorticoids to suppress inflammation and joint swelling in the AIA model⁴⁸. Deletion of the glucocorticoid receptor in T cells prevented the therapeutic effects of glucocorticoids but deletion of the glucocorticoid receptor in stromal cells (which includes synovial fibroblasts, chondrocytes and osteoblasts) did not. Notably, glucocorticoids suppressed T helper 17 (T_H17) type responses [Au: OK? Referring to in the mice with T-cell specific GR deletion].

Comment [MC58]: Yes ok

In 2018, the same group of researchers examined the mediators of glucocorticoid therapy in the STIA model.⁴⁹ Using a combination of approaches (including inducible gene deletion using Cre-lox technology and bone marrow chimeras) they demonstrated that the anti-inflammatory action of glucocorticoids in this model was not mediated via T cells or other cells of haematopoietic origin. Only when the glucocorticoid receptor was present in the stromal cell compartment was dexamethasone treatment able to reduce inflammation. As such, glucocorticoids seem to mediate different anti-inflammatory effects via two entirely separate cell types in two mouse models commonly used to model inflammatory arthritides such as RA. Further adding to the diversity of cellular targets of glucocorticoids, in a model of allergic dermatitis, the presence of glucocorticoid receptor in cells of the monocyte–macrophage or neutrophil lineages seemed essential for maintaining the beneficial effects of [Au: OK? Is this what you meant?] glucocorticoids⁵⁰. These studies clearly show that the effects of glucocorticoids are probably mediated by different cell types in different diseases and that the exact targets cannot be reliably predicted without experimental testing using approaches such as those described above.

Comment [MC59]: No. Glucocorticoids suppressed responses in the wild type mice but not in the T cell specific GR deletion indicating that the GR in T cells regulated Th17 responses.

Comment [MC60]: Yes ok

Although the anti-inflammatory actions of glucocorticoids are generally assumed to be mediated by effects on immune cells, other experiments also suggest a role for the stromal compartment in modulating inflammation. Glucocorticoid signalling in specific cell types can be blocked by ectopic expression of the 11 β HSD2 enzyme. Artificial expression [Au: expression or overexpression?] of 11 β HSD2 in chondrocytes resulted in increased levels of joint inflammation in the AIA and STIA mouse models⁵¹. This finding suggests that glucocorticoids can mediate anti-inflammatory effects via targeting chondrocytes. By contrast, 11 β HSD2 expression in osteoblasts resulted in reduced joint inflammation in mice with STIA⁵². These results indicate that, paradoxically, glucocorticoid signalling in some stromal cells can have pro-inflammatory effects in arthritis. Glucocorticoids are also recognised to have pro-inflammatory effects in other cell types such as microglia⁵³.

Comment [MC61]: Expression. The enzyme is not normally present in chondrocytes so this is referring to the artificial expression of an enzyme that is not normally there

[H1] Mechanisms underlying adverse effects [Au: Shortened title OK?]

Comment [MC62]: Yes ok

Long term use of therapeutic glucocorticoids is associated with a range of adverse effects. The effects that have been studied most extensively are the actions of glucocorticoids on bone, muscle and glucose metabolism (figure 5).

[H2] Effects of glucocorticoids on bone

An excess of glucocorticoids [Au: OK? What would be considered “excess”? Or is this not quantifiable?] is associated with reduced bone mineral density, impaired bone quality and an increased risk of fracture⁷. The relationship between glucocorticoids and bone is particularly complicated in rheumatic diseases as inflammation itself has a detrimental effect on bone⁵⁴. It is likely that glucocorticoid suppression of inflammation has a net positive effect on bone metabolism but that the continued use of glucocorticoids when inflammation is low is detrimental. Glucocorticoids have effects on all the major cells involved in bone metabolism (the specific targets are highlighted in figure 5 and have been reviewed elsewhere^{7, 54}). Glucocorticoids impair osteoblast proliferation and reduce their ability to produce bone matrix proteins³⁹. High doses of glucocorticoids can cause apoptosis of osteocytes, the most abundant cell type within the skeleton and a critical mediator of the balance between bone resorption and formation⁵⁵. Glucocorticoids also stimulate the activity of osteoclasts but during long term treatment the production of osteoclasts [Au: by “production of osteoclasts” are you referring to osteoclast differentiation?] is suppressed by glucocorticoids⁵⁵. At a molecular level, the changes that occur in bone in response to glucocorticoids can be largely explained by the effects of glucocorticoids on inhibiting anabolic bone signalling in osteocytes and osteoblasts; in these cells [Au: OK? Do glucocorticoids stimulate the next effects in both cells types? or just one of these cell types?], glucocorticoids stimulate the expression of inhibitors of anabolic bone signalling and thus reduce bone formation and increase the expression of the pro-osteoclastogenic factor receptor activator of NF-κB ligand (RANKL)⁵⁶. In GR^{dim/dim} mice, the adverse effects of glucocorticoids on the skeleton still occur, despite the reduced capacity of the glucocorticoid receptor to dimerise³⁹. This finding suggests that these adverse effects on bone are mediated through glucocorticoid receptor transrepression [Au: OK?].

Comment [MC63]: Good point. Glucocorticoids are normally present but if levels are too high from tumours or drugs then these problems develop. It might be phrased ‘Exposure to supraphysiological levels of glucocorticoids (either endogenous or pharmacological is associated....’

Comment [MC64]: Glucocorticoids stimulate differentiation of mature osteoclasts but inhibit differentiation of very early precursors. It might be changed to ‘long term treatment the differentiation of early precursors to mature osteoclasts’

Comment [MC65]:

Comment [MC66]: This applies to both cell types (the cell types are hard to tell apart in reality)

Comment [MC67]: Yes ok

[H2] Effects of glucocorticoids on muscle

Long term glucocorticoid use is associated with reduced muscle mass and strength [Au: Could you please reference this statement?]. In patients with RA receiving therapeutic glucocorticoids, muscle wasting is rapid, long lasting and is a considerable morbidity factor that increases the risk of subsequent falls and fractures^{59, 62, 65-67} [Au: I moved this highlighted sentence to here to improve the flow, OK?]. The specific pathways involved in glucocorticoid-induced muscle wasting [Au: OK?] are highlighted in figure 5. In patients

Comment [MC68]: I would suggest original references 59 and 60 (Lofberg et al, wang R et al)

Comment [MC69]: Yes ok

Comment [MC70]: Yes ok

receiving therapeutic glucocorticoids, muscle wasting is mediated by both a robust reduction in anabolic protein synthesis and an increase in protein degradation [Au:OK? (I split up this sentence as it was fairly long)]. The reduction in anabolic protein synthesis is secondary to suppression of the PI3K–AKT–mTOR pathway and downstream targets ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E binding protein 1 (4EBP1, also known as eIF4EBP1) [Au: OK? Do these targets mediate the anti-anabolic effects mentioned next? (or else, how to the two sentences connect?)]. The anti-anabolic effects are mediated by a plethora of changes, including the suppression of anabolic signalling via insulin-like growth factor I (IGF1) and insulin receptor substrate 1 (IRS1), and the induction of the anti-anabolic factors myostatin and DNA damage-inducible transcript 4 protein (DDIT4, also known as REDD1) [Au: Edits OK? I moved this sentence here to improve the flow, OK?]^{57, 60–62}. By contrast, increased protein degradation is mediated by E3-protein ligases, E3 ubiquitin-protein ligase TRIM63 and F-box only protein 32 [Au:OK?], increased activity of the ubiquitin proteasomal degradation pathway, and increased autophagy^{57–59}. The induction of catabolic proteasomal degradation and autophagy seem to be driven through an direct induction of forkhead box protein O1 (FOXO1) by glucocorticoids and an indirect induction [Au: An indirect induction of what? FOXO1?] secondary to suppression of the PI3K–AKT–mTOR pathway^{63, 64}.

[H2] Effects of glucocorticoids on glucose and lipid metabolism

Glucocorticoids have complex effects on the distribution of fat and the regulation of energy substrates at a systemic level^{68, 69}. Glucocorticoids have effects on all the tissues involved in glucose and lipid metabolism (including the liver, muscle, adipose tissue and endocrine pancreas). A coordinated change in systemic energy metabolism is a feature of the stress response; hence, glucocorticoid-induced changes are probably simply a magnification of these changes. Given the diversity of targets of glucocorticoids, no single mechanism or cellular target within these tissues has been identified. Interestingly, some evidence from rodent [Au: meaning mouse?] studies suggest that glucocorticoid-induced changes in bone [Au:OK?] might mediate, at least in part, some of the effects of glucocorticoids on systemic energy metabolism⁷⁰. Mice with ectopic expression of 11 β HSD2 in osteoblasts and osteocytes, and thus an abrogation of glucocorticoid signalling selectively in these tissues, [Au: By these tissues do you mean bone? Or do you mean these cells?] do not develop insulin resistance and glucose intolerance in response to glucocorticoid therapy, unlike their wild-type counterparts. The osteoblast-specific protein osteocalcin [Au: Meaning osteocalcin produced by osteoblasts?] is a potential mediator between bone and energy metabolism [Au: Ok? On the basis of what study(s)? Could you reference the study here?]. In other contexts, osteocalcin can improve insulin sensitivity through a variety of actions on the liver and pancreas⁷¹, but osteocalcin levels [Au: meaning expression or activity?] are notably inhibited by glucocorticoids. In support of this concept, mice with heterotopic

Comment [MC71]: Yes ok

Comment [MC72]: The other way around. The most downstream effects are on pi3k etc and these effects are secondary to changes in the pathways described next.

Comment [MC73]: ok

Comment [MC74]: ok

Comment [MC75]: should be 'a' rather than an

Comment [MC76]: yes FOXO1

Comment [MC77]: yes mouse

Comment [MC78]: yes ok

Comment [MC79]: cells is more accurate please change

Comment [MC80]: meaning that osteocalcin is only made by osteoblasts. It is not made anywhere else under normal circumstances

Comment [MC81]: please use reference 71 (lee et al.)

Comment [MC82]: actually this means the levels in the blood. Maybe 'the concentration of osteocalcin in the blood is notably' would be better

expression of osteocalcin in the liver are protected against the effects of glucocorticoids on metabolism⁷⁰.

[H1] Therapeutic implications [Au: H1 subheading OK?]

Although the mechanisms underlying the adverse effects of glucocorticoids are well defined (figure 5), this information has only resulted in approaches for reducing the effects of glucocorticoids on bone [Au: OK? is this what you meant? Or did you mean in the context of bone diseases (in which case, which diseases are you referring to)?]^{7, 12, 70}. Notably, the cessation of therapeutic glucocorticoids results in a gradual recovery of bone mass and a return of normal anabolic bone formation over time⁷². By contrast, although further confirmatory studies are required, muscle loss associated with intra-muscular glucocorticoid injections seems to occur rapidly and has a limited capacity to return to pre-treatment levels⁶⁵. Currently, anabolic and anti-catabolic treatments to manage muscle loss in this context are limited to exercise interventions, for which limited evidence of their efficacy in rheumatic diseases is available [Au: OK?]. A hope for many years has been that SEGRAs might retain the anti-inflammatory activity of glucocorticoids but have reduced effects on metabolism. The development of systemically-administered SEGRAs has proven difficult and no SEGRA has yet made its way into clinical use in rheumatic diseases⁷³⁻⁷⁵. However, one potential SEGRA, fosdagrocorat, is currently being evaluated in the context of treatment of RA⁷⁵. In the phase 2a study, fosdagrocorat [Au: OK?] treatment resulted in a reduction in disease activity [Au: reduction compared with baseline, or reduction compared with a control group?] with no notable adverse effects after 2 weeks. A follow up 12 weeks study in 323 patients with moderate to severe RA has compared various doses of fosdagrocorat and prednisone against a placebo, and has had encouraging results [Au: Please reference this study here]. At doses that gave equivalent ACR response rates [Au: Which ACR response rate? ACR20?] to prednisone [Au: Prednisone at what dose - the standard recommended dose?], fosdagrocorat was associated with a reduction in levels of glycosylated haemoglobin subunit β [Au: OK?] whereas prednisone treatment was not [Au: What is the relevance of reduced levels of glycosylated haemoglobin? Please clarify for the non-specialist reader (i.e. how this is linked to glycaemia)]. This finding suggests that this drug has the potential to suppress inflammation (through repression) but has less effect on glycaemic control than currently-used glucocorticoids [Au: OK? Or prednisone specifically?] (owing to reduced transactivation). Further trials of this medication in RA and other conditions are awaited.

Another notable adverse effect of glucocorticoid therapy is suppression of adrenal function. This effect is caused by feedback of glucocorticoids on the hypothalamus and pituitary glands, resulting in inhibition of corticotropin-releasing hormone and adrenocorticotrophic hormone protein synthesis [Au: Clarify what these enzymes are involved in (such as cortisol production) (for non-specialist readers)?]. Up to one third of patients with RA treated with low-dose glucocorticoids have clinically notable suppression of adrenal

Comment [MC83]: yes ok

Comment [MC84]: this is the correct meaning

Comment [MC85]: yes ok

Comment [MC86]: yes ok

Comment [MC87]: compared to baseline

Comment [MC88]: Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019.

Comment [MC89]: Yes ACR20

Comment [MC90]: The study was complex using various doses but for these analyses the prednisone dose was 10mg per day

Comment [MC91]: No. This is actually HbA1c so it would be the A chain. However, the standard term used is glycosylated haemoglobin or HbA1c.

Comment [MC92]: I think any clinician will be familiar with HbA1c etc. However, after haemoglobin you could add (an indicator of average blood glucose levels over time)

Comment [MC93]: I would stick with glucocorticoids since highly related forms such as prednisolone are used in some parts of the world.

Comment [MC94]: This would be too complex. There are about 8 enzymes involved in the adrenal alone. The sites of negative feedback for CRH are complex involving lots of brain areas. Most clinicians know that glucocorticoids switch off the adrenals.

function⁷⁶. Glucocorticoid feedback at the hypothalamus and the pituitary seem to depend on the transrepression function of glucocorticoids^{77,78} and thus SEGRAs would be expected to also suppress endogenous cortisol production. In this situation, patients treated with SEGRAs would have no glucocorticoid available for transactivation functions. This effect could potentially lead to glucocorticoid deficiency in tissues that depend on transactivation for their normal metabolic function, the consequences of which are unclear [Au: OK?].

Comment [MC95]: Yes ok

A clinical problem that remains unaddressed is that of 'glucocorticoid resistance'. This term is generally used to describe situations in which particular diseases or inflammatory pathways that are usually responsive to glucocorticoids fail to respond to glucocorticoid treatment or lose sensitivity to glucocorticoids over time. The mechanistic basis for glucocorticoid resistance is unclear but possible mechanisms involve reduced glucocorticoid receptor expression in target tissues, upregulated expression of specific glucocorticoid receptor isoforms that are less effective in suppressing inflammation in the target tissues [Au: OK?], disease-induced changes to chromatin structures that result in reduced access of glucocorticoid receptors to GREs or the switching on of inflammatory pathways that are intrinsically resistant to glucocorticoid suppression⁷⁹. Unfortunately, attempts to reverse or overcome glucocorticoid resistance have been unsuccessful to date. One approach that has been attempted has been to pharmacologically open chromatin to enable access of the glucocorticoid receptor to otherwise hidden GREs in patients with chronic obstructive pulmonary disease [Au: Could you please reference this statement?]. This approach was tested on the basis of in vitro data indicating that low-dose theophylline (a methylxanthine drug currently used in the treatment of respiratory diseases [Au: Addition OK?]) could stimulate the activity of histone deacetylases important for promoting glucocorticoid sensitivity [Au: OK?]⁸⁰. Unfortunately, in a large randomised controlled trial, theophylline did not improve the effectiveness of inhaled glucocorticoids in patients with chronic obstructive pulmonary disease⁸¹.

Comment [MC96]: Yes ok

Comment [MC97]: This would be the same as below ref 80 (Ito et al)

Comment [MC98]: Yes ok

Comment [MC99]: Yes ok

[H1] Conclusion

In the first two decades after the introduction of cortisol and cortisone, structural modification of glucocorticoids led to the successful introduction of oral and intravenous therapeutics that we still use today. These glucocorticoids have a high tissue penetration, a prolonged half-life and high affinity for the glucocorticoid receptor. Subsequent advances in modulating glucocorticoid properties in other medical disciplines have generally been on the basis of manipulating the pharmacokinetic properties of glucocorticoids to better target drugs to specific tissues (and thus limit systemic adverse effects) or to limit their activity to specific times of the day, rather than manipulating the molecular mechanisms of action of these drugs. This trend looks set to continue given the difficulty in unravelling the complex effects of glucocorticoids at a cellular level and the advances in development of novel drug delivery systems.

The actual cells and cellular targets most important to the action of glucocorticoids remain obscure for most rheumatic diseases. This lack of knowledge prevents the development of more specific therapeutic agents on the basis of how glucocorticoids work. Without these more specific agents, glucocorticoid use in these conditions is likely to continue. The research approaches most likely to lead to specific targets include genetically modified mice with tissue specific alteration of glucocorticoid sensitivity and transcriptome studies using primary human cells. [Au: Could you perhaps comment on what the future direction is for this aspect of glucocorticoid therapy - i.e. are efforts still ongoing to understand these underlying mechanisms that might still be informative in future?]

Comment [MC100]:

Comment [MC101]: Hopefully addressed this weakness

In the meantime, glucocorticoids will probably remain important drugs, particularly during initial disease management, for rapid control of disease flare and, for some people, for long term maintenance therapy at a low dose. In these situations, structured approaches to 'glucocorticoid stewardship' will be needed to ensure patients are treated with the minimum dose of glucocorticoids required to achieve the beneficial effects.

References:

1. Hench PS, Kendall EC, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound e) and of pituitary adrenocorticotrophic hormone on rheumatoid arthritis. *Proceedings of the staff meetings. Mayo Clinic.* 1949;24:181-197
2. Black RJ, Lester S, Buchbinder R, Barrett C, Lassere M, March L, Whittle S, Hill CL. Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: A drug use study from a prospective national biologics registry. *Arthritis Res Ther.* 2017;19:253
3. van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the united kingdom. *QJM.* 2000;93:105-111
4. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the united states: A general population perspective. *Arthritis care & research.* 2013;65:294-298
5. Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. *PloS one.* 2019;14:e0210459
6. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. *J.Bone Miner.Res.* 2000;15:993-1000
7. Hardy RS, Zhou H, Seibel MJ, Cooper MS. Glucocorticoids and bone: Consequences of endogenous and exogenous excess and replacement therapy. *Endocrine reviews.* 2018
8. Black RJ, Goodman SM, Ruediger C, Lester S, Mackie SL, Hill CL. A survey of glucocorticoid adverse effects and benefits in rheumatic diseases: The patient perspective. *J Clin Rheumatol.* 2017;23:416-420
9. Costello R, Patel R, Humphreys J, McBeth J, Dixon WG. Patient perceptions of glucocorticoid side effects: A cross-sectional survey of users in an online health community. *BMJ open.* 2017;7:e014603
10. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. *Cell.* 2002;110:93-105

11. Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. *Comprehensive Physiology*. 2014;4:965-994
12. Hardy RS, Fenton C, Croft AP, Naylor AJ, Begum R, Desanti G, Buckley CD, Lavery G, Cooper MS, Raza K. 11 beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis. *J Autoimmun*. 2018;92:104-113
13. Coutinho AE, Gray M, Brownstein DG, Salter DM, Sawatzky DA, Clay S, Gilmour JS, Seckl JR, Savill JS, Chapman KE. 11 β -hsd type 1, but not type 2, deficiency worsens acute inflammation and experimental arthritis in mice. *Endocrinology*. 2012;153:234-240
14. Jones IA, Togashi R, Wilson ML, Heckmann N, Vangsness CT, Jr. Intra-articular treatment options for knee osteoarthritis. *Nature reviews. Rheumatology*. 2019;15:77-90
15. Buttgerit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (capra-1): A double-blind, randomised controlled trial. *Lancet*. 2008;371:205-214
16. Buttgerit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, Supronik J, Szombati I, Romer U, Witte S, Saag KG. Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (capra-2). *Ann Rheum Dis*. 2013;72:204-210
17. Wu T, Jiang J, Yang L, Li H, Zhang W, Chen Y, Zhao B, Kong B, Lu P, Zhao Z, Zhu J, Fu Z. Timing of glucocorticoid administration determines severity of lipid metabolism and behavioral effects in rats. *Chronobiology international*. 2017;34:78-92
18. Caratti G, Iqbal M, Hunter L, Kim D, Wang P, Vonslow RM, Begley N, Tetley AJ, Woodburn JL, Pariollaud M, Maidstone R, Donaldson IJ, Zhang Z, Ince LM, Kitchen G, Baxter M, Poolman TM, Daniels DA, Stirling DR, Brocker C, Gonzalez F, Loudon AS, Bechtold DA, Rattray M, Matthews LC, Ray DW. Reverba couples the circadian clock to hepatic glucocorticoid action. *The Journal of clinical investigation*. 2018;128:4454-4471
19. Kalafatakis K, Russell GM, Harmer CJ, Munafo MR, Marchant N, Wilson A, Brooks JC, Durant C, Thakrar J, Murphy P, Thai NJ, Lightman SL. Ultradian rhythmicity of plasma cortisol is necessary for normal emotional and cognitive responses in man. *Proceedings of the National Academy of Sciences of the United States of America*. 2018;115:E4091-E4100
20. Luhder F, Reichardt HM. Novel drug delivery systems tailored for improved administration of glucocorticoids. *International journal of molecular sciences*. 2017;18
21. Conaghan PG, Cohen SB, Berenbaum F, Lufkin J, Johnson JR, Bodick N. Brief report: A phase iib trial of a novel extended-release microsphere formulation of triamcinolone acetonide for intraarticular injection in knee osteoarthritis. *Arthritis & rheumatology (Hoboken, N.J.)*. 2018;70:204-211
22. Joshi N, Yan J, Levy S, Bhagchandani S, Slaughter KV, Sherman NE, Amirault J, Wang Y, Riegel L, He X, Rui TS, Valic M, Vemula PK, Miranda OR, Levy O, Gravallesse EM, Aliprantis AO, Ermann J, Karp JM. Towards an arthritis flare-responsive drug delivery system. *Nature communications*. 2018;9:1275
23. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. *Nature reviews. Immunology*. 2017;17:233-247
24. Oakley RH, Webster JC, Jewell CM, Sar M, Cidlowski JA. Immunocytochemical analysis of the glucocorticoid receptor alpha isoform (gralpha) using gralpha-specific antibody. *Steroids*. 1999;64:742-751
25. Kino T, Su YA, Chrousos GP. Human glucocorticoid receptor isoform beta: Recent understanding of its potential implications in physiology and pathophysiology. *Cell Mol Life Sci*. 2009;66:3435-3448
26. Derijk RH, Schaaf MJ, Turner G, Datson NA, Vreugdenhil E, Cidlowski J, de Kloet ER, Emery P, Sternberg EM, Detera-Wadleigh SD. A human glucocorticoid receptor gene variant that increases the stability of the glucocorticoid receptor beta-isoform mrna is associated with rheumatoid arthritis. *J Rheumatol*. 2001;28:2383-2388

27. Oakley RH, Ramamoorthy S, Foley JF, Busada JT, Lu NZ, Cidlowski JA. Glucocorticoid receptor isoform-specific regulation of development, circadian rhythm, and inflammation in mice. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2018;32:5258-5271
28. Cao Y, Bender IK, Konstantinidis AK, Shin SC, Jewell CM, Cidlowski JA, Schleimer RP, Lu NZ. Glucocorticoid receptor translational isoforms underlie maturational stage-specific glucocorticoid sensitivities of dendritic cells in mice and humans. *Blood*. 2013;121:1553-1562
29. Hua G, Paulen L, Chambon P. Gr sumoylation and formation of an sumo-smrt/ncor1-hdac3 repressing complex is mandatory for gc-induced ir ngre-mediated transrepression. *Proceedings of the National Academy of Sciences of the United States of America*. 2016;113:E626-634
30. Wilkinson L, Verhoog N, Louw A. Novel role for receptor dimerization in post-translational processing and turnover of the gralpha. *Scientific reports*. 2018;8:14266
31. Kino T, Chrousos GP. Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: Circadian rhythm-associated alterations of glucocorticoid actions in target tissues. *Molecular and cellular endocrinology*. 2011;336:23-30
32. Nahar J, Haam J, Chen C, Jiang Z, Glatzer NR, Muglia LJ, Dohanich GP, Herman JP, Tasker JG. Rapid nongenomic glucocorticoid actions in male mouse hypothalamic neuroendocrine cells are dependent on the nuclear glucocorticoid receptor. *Endocrinology*. 2015;156:2831-2842
33. Deng Q, Riquelme D, Trinh L, Low MJ, Tomic M, Stojilkovic S, Aguilera G. Rapid glucocorticoid feedback inhibition of acth secretion involves ligand-dependent membrane association of glucocorticoid receptors. *Endocrinology*. 2015;156:3215-3227
34. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, Saklatvala J, Clark AR. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. *J.Exp.Med*. 2006;203:1883-1889
35. Vettorazzi S, Bode C, Dejager L, Frappart L, Shelest E, Klassen C, Tasdogan A, Reichardt HM, Libert C, Schneider M, Weih F, Henriette Uhlenhaut N, David JP, Graler M, Kleiman A, Tuckermann JP. Glucocorticoids limit acute lung inflammation in concert with inflammatory stimuli by induction of sphk1. *Nature communications*. 2015;6:7796
36. Yang YH, Morand EF, Getting SJ, Paul-Clark M, Liu DL, Yona S, Hannon R, Buckingham JC, Perretti M, Flower RJ. Modulation of inflammation and response to dexamethasone by annexin 1 in antigen-induced arthritis. *Arthritis Rheum*. 2004;50:976-984
37. Reichardt HM, Kaestner KH, Tuckermann J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G. DNA binding of the glucocorticoid receptor is not essential for survival. *Cell*. 1998;93:531-541
38. Kleiman A, Hubner S, Rodriguez Parkitna JM, Neumann A, Hofer S, Weigand MA, Bauer M, Schmid W, Schutz G, Libert C, Reichardt HM, Tuckermann JP. Glucocorticoid receptor dimerization is required for survival in septic shock via suppression of interleukin-1 in macrophages. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2012;26:722-729
39. Rauch A, Seitz S, Baschant U, Schilling AF, Illing A, Stride B, Kirilov M, Mandic V, Takacz A, Schmidt-Ullrich R, Ostermay S, Schinke T, Spanbroek R, Zaiss MM, Angel PE, Lerner UH, David JP, Reichardt HM, Amling M, Schutz G, Tuckermann JP. Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. *Cell Metab*. 2010;11:517-531
40. Sacta MA, Chinenov Y, Rogatsky I. Glucocorticoid signaling: An update from a genomic perspective. *Annual review of physiology*. 2016;78:155-180
41. Lim HW, Uhlenhaut NH, Rauch A, Weiner J, Hubner S, Hubner N, Won KJ, Lazar MA, Tuckermann J, Steger DJ. Genomic redistribution of gr monomers and dimers mediates transcriptional response to exogenous glucocorticoid in vivo. *Genome research*. 2015;25:836-844

42. Love MI, Huska MR, Jurk M, Schopflin R, Starick SR, Schwahn K, Cooper SB, Yamamoto KR, Thomas-Chollier M, Vingron M, Meijsing SH. Role of the chromatin landscape and sequence in determining cell type-specific genomic glucocorticoid receptor binding and gene regulation. *Nucleic acids research*. 2017;45:1805-1819
43. Wang C, Nanni L, Novakovic B, Megchelenbrink W, Kuznetsova T, Stunnenberg HG, Ceri S, Logie C. Extensive epigenomic integration of the glucocorticoid response in primary human monocytes and in vitro derived macrophages. *Scientific reports*. 2019;9:2772
44. Franco LM, Gadkari M, Howe KN, Sun J, Kardava L, Kumar P, Kumari S, Hu Z, Fraser IDC, Moir S, Tsang JS, Germain RN. Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses. *J Exp Med*. 2019;216:384-406
45. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O'Shea JJ, Chrousos GP, Bornstein SR. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2002;16:61-71
46. Clayton SA, Jones SW, Kurowska-Stolarska M, Clark AR. The role of micrnas in glucocorticoid action. *The Journal of biological chemistry*. 2018;293:1865-1874
47. Whirlledge S, DeFranco DB. Glucocorticoid signaling in health and disease: Insights from tissue-specific gr knockout mice. *Endocrinology*. 2018;159:46-64
48. Baschant U, Frappart L, Rauchhaus U, Bruns L, Reichardt HM, Kamradt T, Brauer R, Tuckermann JP. Glucocorticoid therapy of antigen-induced arthritis depends on the dimerized glucocorticoid receptor in t cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2011;108:19317-19322
49. Koenen M, Culemann S, Vettorazzi S, Caratti G, Frappart L, Baum W, Kronke G, Baschant U, Tuckermann JP. Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis. *Annals of the rheumatic diseases*. 2018;77:1610-1618
50. Tuckermann JP, Kleiman A, Moriggl R, Spanbroek R, Neumann A, Illing A, Clausen BE, Stride B, Forster I, Habenicht AJ, Reichardt HM, Tronche F, Schmid W, Schutz G. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. *The Journal of clinical investigation*. 2007;117:1381-1390
51. Tu J, Stoner S, Fromm PD, Wang T, Chen D, Tuckermann J, Cooper MS, Seibel MJ, Zhou H. Endogenous glucocorticoid signaling in chondrocytes attenuates joint inflammation and damage. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2018;32:478-487
52. Buttgereit F, Zhou H, Kalak R, Gaber T, Spies CM, Huscher D, Straub RH, Modzelewski J, Dunstan CR, Seibel MJ. Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates k/bxn mouse serum-induced arthritis in vivo. *Arthritis Rheum*. 2009;60:1998-2007
53. Frank MG, Thompson BM, Watkins LR, Maier SF. Glucocorticoids mediate stress-induced priming of microglial pro-inflammatory responses. *Brain, behavior, and immunity*. 2012;26:337-345
54. Briot K, Geusens P, Em Bultink I, Lems WF, Roux C. Inflammatory diseases and bone fragility. *Osteoporos Int*. 2017;28:3301-3314
55. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. *J.Clin.Invest*. 1998;102:274-282
56. Piemontese M, Xiong J, Fujiwara Y, Thostenson JD, O'Brien CA. Cortical bone loss caused by glucocorticoid excess requires rankl production by osteocytes and is associated with reduced opg expression in mice. *American journal of physiology. Endocrinology and metabolism*. 2016;311:E587-593

57. Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of *redd1*. *The Journal of biological chemistry*. 2006;281:39128-39134
58. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, Stitt TN, Yancopoulos GD, Glass DJ. Identification of ubiquitin ligases required for skeletal muscle atrophy. *Science*. 2001;294:1704-1708
59. Lofberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, Price SR, Bergstrom J, Alvestrand A. Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle. *Eur J Clin Invest*. 2002;32:345-353
60. Wang R, Jiao H, Zhao J, Wang X, Lin H. Glucocorticoids enhance muscle proteolysis through a myostatin-dependent pathway at the early stage. *PLoS one*. 2016;11:e0156225
61. Hu Z, Wang H, Lee IH, Du J, Mitch WE. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. *The Journal of clinical investigation*. 2009;119:3059-3069
62. Schakman O, Gilson H, de Coninck V, Lause P, Verniers J, Havaux X, Ketelslegers JM, Thissen JP. Insulin-like growth factor-i gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. *Endocrinology*. 2005;146:1789-1797
63. Qin W, Pan J, Qin Y, Lee DN, Bauman WA, Cardozo C. Identification of functional glucocorticoid response elements in the mouse *foxo1* promoter. *Biochem Biophys Res Commun*. 2014;450:979-983
64. Cho JE, Fournier M, Da XY, Lewis MI. Time course expression of *foxo* transcription factors in skeletal muscle following corticosteroid administration. *J Appl Physiol*. 2010;108:137-145
65. Lemmey AB, Wilkinson TJ, Perkins CM, Nixon LA, Sheikh F, Jones JG, Ahmad YA, O'Brien T D. Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis. *Eur J Rheumatol*. 2018;5:160-164
66. Hilton-Jones D. Diagnosis and treatment of inflammatory muscle diseases. *Journal of neurology, neurosurgery, and psychiatry*. 2003;74 Suppl 2:ii25-ii31
67. Tomas FM, Munro HN, Young VR. Effect of glucocorticoid administration on the rate of muscle protein breakdown in vivo in rats, as measured by urinary excretion of n tau-methylhistidine. *Biochem J*. 1979;178:139-146
68. Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. *Metabolism*. 2011;60:1500-1510
69. Manolopoulos KN, O'Reilly MW, Bujalska IJ, Tomlinson JW, Arlt W. Acute hypercortisolemia exerts depot-specific effects on abdominal and femoral adipose tissue function. *The Journal of clinical endocrinology and metabolism*. 2017;102:1091-1101
70. Brennan-Speranza TC, Henneicke H, Gasparini SJ, Blankenstein KI, Heinevetter U, Cogger VC, Svistounov D, Zhang Y, Cooney GJ, Buttgerit F, Dunstan CR, Gundberg C, Zhou H, Seibel MJ. Osteoblasts mediate the adverse effects of glucocorticoids on bone metabolism. *J.Clin.Invest*. 2012;122:4172-4189
71. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. *Cell*. 2007;130:456-469
72. Steinbuch M, Youket TE, Cohen S. Oral glucocorticoid use is associated with an increased risk of fracture. *Osteoporos Int*. 2004;15:323-328
73. Desmet SJ, De Bosscher K. Glucocorticoid receptors: Finding the middle ground. *The Journal of clinical investigation*. 2017;127:1136-1145
74. Safy M, de Hair MJH, Jacobs JWG, Buttgerit F, Kraan MC, van Laar JM. Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. *PLoS one*. 2017;12:e0188810

75. Stock T, Fleishaker D, Wang X, Mukherjee A, Mebus C. Improved disease activity with fosdagrocorat (pf-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: A phase 2 randomized study. *International journal of rheumatic diseases*. 2017;20:960-970
76. Borresen SW, Klose M, Baslund B, Rasmussen AK, Hilsted L, Friis-Hansen L, Loch H, Hansen A, Hetland ML, Lydolph MC, Feldt-Rasmussen U. Adrenal insufficiency is seen in more than one-third of patients during ongoing low-dose prednisolone treatment for rheumatoid arthritis. *European journal of endocrinology / European Federation of Endocrine Societies*. 2017;177:287-295
77. Phillips A, Maira M, Mullick A, Chamberland M, Lesage S, Hugo P, Drouin J. Antagonism between nur77 and glucocorticoid receptor for control of transcription. *Molecular and cellular biology*. 1997;17:5952-5959
78. Yamamori E, Iwasaki Y, Taguchi T, Nishiyama M, Yoshida M, Asai M, Oiso Y, Itoi K, Kambayashi M, Hashimoto K. Molecular mechanisms for corticotropin-releasing hormone gene repression by glucocorticoid in be(2)c neuronal cell line. *Molecular and cellular endocrinology*. 2007;264:142-148
79. Newton R, Shah S, Altonsy MO, Gerber AN. Glucocorticoid and cytokine crosstalk: Feedback, feedforward, and co-regulatory interactions determine repression or resistance. *The Journal of biological chemistry*. 2017;292:7163-7172
80. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC, Barnes PJ. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. *N.Engl.J.Med*. 2005;352:1967-1976
81. Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, De Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D. Effect of theophylline as adjunct to inhaled corticosteroids on exacerbations in patients with copd: A randomized clinical trial. *JAMA*. 2018;320:1548-1559
82. Liberman AC, Druker J, Perone MJ, Arzt E. Glucocorticoids in the regulation of transcription factors that control cytokine synthesis. *Cytokine & growth factor reviews*. 2007;18:45-56
83. Ramirez F, Fowell DJ, Puklavec M, Simmonds S, Mason D. Glucocorticoids promote a th2 cytokine response by cd4+ t cells in vitro. *Journal of immunology*. 1996;156:2406-2412
84. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, Frucht DM, Chrousos GP, O'Shea JJ. Inhibition of th1 immune response by glucocorticoids: Dexamethasone selectively inhibits il-12-induced stat4 phosphorylation in t lymphocytes. *Journal of immunology*. 2000;164:1768-1774
85. Migliorati G, Pagliacci C, Moraca R, Crocicchio F, Nicoletti I, Riccardi C. Glucocorticoid-induced apoptosis of natural killer cells and cytotoxic t lymphocytes. *Pharmacological research*. 1992;26 Suppl 2:26-27
86. Schleimer RP, Jacques A, Shin HS, Lichtenstein LM, Plaut M. Inhibition of t cell-mediated cytotoxicity by anti-inflammatory steroids. *Journal of immunology*. 1984;132:266-271
87. Lill-Elghanian D, Schwartz K, King L, Fraker P. Glucocorticoid-induced apoptosis in early b cells from human bone marrow. *Experimental biology and medicine*. 2002;227:763-770
88. Cupps TR, Gerrard TL, Falkoff RJ, Whalen G, Fauci AS. Effects of in vitro corticosteroids on b cell activation, proliferation, and differentiation. *The Journal of clinical investigation*. 1985;75:754-761
89. Zhou J, Liu DF, Liu C, Kang ZM, Shen XH, Chen YZ, Xu T, Jiang CL. Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. *Allergy*. 2008;63:1177-1185
90. Barczyk K, Ehrchen J, Tenbrock K, Ahlmann M, Kneidl J, Viemann D, Roth J. Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor a3. *Blood*. 2010;116:446-455

91. McColl A, Bournazos S, Franz S, Perretti M, Morgan BP, Haslett C, Dransfield I. Glucocorticoids induce protein s-dependent phagocytosis of apoptotic neutrophils by human macrophages. *Journal of immunology*. 2009;183:2167-2175
92. Franchimont D. Overview of the actions of glucocorticoids on the immune response: A good model to characterize new pathways of immunosuppression for new treatment strategies. *Annals of the New York Academy of Sciences*. 2004;1024:124-137
93. Zhou JY, Zhong HJ, Yang C, Yan J, Wang HY, Jiang JX. Corticosterone exerts immunostimulatory effects on macrophages via endoplasmic reticulum stress. *The British journal of surgery*. 2010;97:281-293
94. Filep JG, Delalandre A, Payette Y, Foldes-Filep E. Glucocorticoid receptor regulates expression of I-selectin and cd11/cd18 on human neutrophils. *Circulation*. 1997;96:295-301
95. Cavalcanti DM, Lotufo CM, Borelli P, Ferreira ZS, Markus RP, Farsky SH. Endogenous glucocorticoids control neutrophil mobilization from bone marrow to blood and tissues in non-inflammatory conditions. *British journal of pharmacology*. 2007;152:1291-1300
96. Khoury P, Stokes K, Gadkari M, Makiya MA, Legrand F, Hu Z, Klion A, Franco LM. Glucocorticoid-induced eosinopenia in humans can be linked to early transcriptional events. *Allergy*. 2018;73:2076-2079
97. Sivertson KL, Seeds MC, Long DL, Peachman KK, Bass DA. The differential effect of dexamethasone on granulocyte apoptosis involves stabilization of mcl-1 in neutrophils but not in eosinophils. *Cellular immunology*. 2007;246:34-45
98. Mogensen TH, Berg RS, Paludan SR, Ostergaard L. Mechanisms of dexamethasone-mediated inhibition of toll-like receptor signaling induced by neisseria meningitidis and streptococcus pneumoniae. *Infection and immunity*. 2008;76:189-197
99. Chen F, Zhang L, OuYang Y, Guan H, Liu Q, Ni B. Glucocorticoid induced osteoblast apoptosis by increasing e4bp4 expression via up-regulation of bim. *Calcified tissue international*. 2014;94:640-647
100. Swanson C, Lorentzon M, Conaway HH, Lerner UH. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (nf-kappaB) ligand, osteoprotegerin, and receptor activator of nf-kappaB in mouse calvarial bones. *Endocrinology*. 2006;147:3613-3622
101. Humphrey EL, Williams JH, Davie MW, Marshall MJ. Effects of dissociated glucocorticoids on opg and rankl in osteoblastic cells. *Bone*. 2006;38:652-661
102. Huang Y, Cai GQ, Peng JP, Shen C. Glucocorticoids induce apoptosis and matrix metalloproteinase-13 expression in chondrocytes through the nox4/ROS/p38 MAPK pathway. *The Journal of steroid biochemistry and molecular biology*. 2018;181:52-62
103. Braun TP, Marks DL. The regulation of muscle mass by endogenous glucocorticoids. *Frontiers in physiology*. 2015;6:12
104. Troncoso R, Paredes F, Parra V, Gatica D, Vasquez-Trincado C, Quiroga C, Bravo-Sagua R, Lopez-Crisosto C, Rodriguez AE, Oyarzun AP, Kroemer G, Lavandro S. Dexamethasone-induced autophagy mediates muscle atrophy through mitochondrial clearance. *Cell cycle*. 2014;13:2281-2295
105. Hardy RS, Filer A, Cooper MS, Parsonage G, Raza K, Hardie DL, Rabbitt EH, Stewart PM, Buckley CD, Hewison M. Differential expression, function and response to inflammatory stimuli of 11beta-hydroxysteroid dehydrogenase type 1 in human fibroblasts: A mechanism for tissue-specific regulation of inflammation. *Arthritis research & therapy*. 2006;8:R108
106. Durmus M, Karaaslan E, Ozturk E, Gulec M, Iraz M, Edali N, Ersoy MO. The effects of single-dose dexamethasone on wound healing in rats. *Anesthesia and analgesia*. 2003;97:1377-1380
107. Pitzalis C, Pipitone N, Bajocchi G, Hall M, Goulding N, Lee A, Kingsley G, Lanchbury J, Panayi G. Corticosteroids inhibit lymphocyte binding to endothelium and intercellular adhesion: An

additional mechanism for their anti-inflammatory and immunosuppressive effect. *Journal of immunology*. 1997;158:5007-5016

108. Pitzalis C, Pipitone N, Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. *Annals of the New York Academy of Sciences*. 2002;966:108-118

109. Elftman MD, Norbury CC, Bonneau RH, Truckenmiller ME. Corticosterone impairs dendritic cell maturation and function. *Immunology*. 2007;122:279-290

Acknowledgements

The authors ~~thank~~ acknowledge the support of the Versus Arthritis funded Research into Inflammatory Arthritis Centre at the University of Birmingham. ~~xxxx~~ [Au: This is an OPTIONAL section. Space is available to note any acknowledgements you would like to be included with the article, such as grant support or editorial assistance]

Author contributions

The authors contributed equally to all aspects of the article.

Competing interests

The authors declare no competing interests. [Au:OK?]

Comment [MC102]: Yes ok

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary information is available for this paper at <https://doi.org/10.1038/s415XX-XXX-XXXX-X>

Key points

- Therapeutic glucocorticoids are powerful, broad spectrum anti-inflammatory agents that are limited by a wide range of adverse effects.
- The specific mechanisms of action by which glucocorticoids mediate anti-inflammatory effects in rheumatic diseases are still unclear, hindering the development of novel therapeutic agents [Au: OK (i.e. I merged the last bullet point you had to this one, as they were very similar)]

Comment [MC103]: Yes ok

- Approaches to the study of glucocorticoid actions have been complicated by the widespread use of animal tissues and transformed cell lines rather than human primary cells.
- The development of novel glucocorticoids that 'dissociate' molecular transrepression from transactivation have proven difficult, however, one such dissociated glucocorticoid is undergoing clinical trials in patients with inflammatory arthritis.
- The use of genetically modified mice with altered glucocorticoid sensitivity in specific tissues and transcriptomic studies using primary human cells are the most promising approaches to define the most important cellular and molecular targets of glucocorticoids.

[Au: Ideally, you should have 4-6 key points that mention the main aspects covered in this Review. Currently, these points only mentioned the unknown mechanisms and limitations of mouse models. Could you include some additional key points - perhaps one on glucocorticoid receptor signalling, one on cellular targets and one on therapeutic implications - to help give a nice coverage of the different aspects covered in this Review?]

Comment [MC104]: Hopefully addressed

Figure 1: Natural and synthetic glucocorticoids [Au: OK?]

Comment [MC105]: Yes ok

The molecular structures of the endogenous glucocorticoid cortisol and common synthetic glucocorticoid derivatives prednisolone, methylprednisolone, triamcinolone, dexamethasone and betamethasone. A hydroxyl group at position 11 of the steroid ring (highlighted in red) is critical to the activity of these glucocorticoids.

[Au: For part A, why is one of the "HO"s in red? Is this a key position shared by all the derivatives?]

Comment [MC106]: Hopefully addressed

Figure 2: Systemic and local metabolism and inactivation of circulating glucocorticoids.

Circulating glucocorticoids shuttle between their inactive form, mediated by dehydrogenase inactivation by corticosteroid 11 β -dehydrogenase isozyme 2 (11 β HSD2) in the kidneys, and their active form, mediated by oxoreductase activation by 11 β HSD1 in the liver. Intracellular pre-receptor metabolism determines local activation and inactivation of glucocorticoids. Cells expressing 11 β HSD1 increase local glucocorticoid activation and glucocorticoid receptor ligand binding. By contrast, cells expressing 11 β HSD2 rapidly inactivate glucocorticoids, protecting the mineralocorticoid receptor from inappropriate glucocorticoid ligand binding and activation. 11keto and 11 β -hydroxyl steroids are irreversibly 5 α or 5 β reduced to their inactive metabolites tetrahydrocortisone, 5 α -tetrahydrocortisol and tetrahydrocortisol by the actions 5 α and 5 β reductase. Further metabolism by 20 α and 20 β reductase yields inactive α and β cortolones and cortols. THE, tetrahydrocortisone;

[Au: What does "ALDO" refer to in this figure?]

Comment [MC107]: ALDO is aldosterone

Figure 3: Glucocorticoid receptors

A) The structural domains of the glucocorticoid receptor isoforms glucocorticoid receptor α ($GR\alpha$) and $GR\beta$. B) During glucocorticoid receptor binding, homodimers of $GR\alpha$ bind to the glucocorticoid response element (GRE) to regulate gene expression whereas $GR\alpha$ – $GR\beta$ heterodimers function as dominant negative inhibitors, antagonising the activity of $GR\alpha$. DBD (DNA binding domain); LBD (ligand binding domain)

Figure 4: Molecular mechanisms of glucocorticoid receptor signalling.

Glucocorticoid receptor signalling can involve transactivation (a), transpression (b) or other mechanisms (c). These mechanisms can involve either dimeric or monomeric receptors; can involve direct binding of these receptor complexes to DNA or indirect effects on other DNA binding factors; or can sometimes involve interactions in the cytoplasm or cell membrane. For direct dimer transactivation and transrepression, ligand-bound $GR\alpha$ homodimers bind to glucocorticoid response elements (GREs) to elicit either direct induction or suppression of downstream gene expression. For monomer signalling, ligand-bound monomeric $GR\alpha$ bind to GREs and recruit co-activators or co-repressors to influence secondary transcription factor regulation of gene expression (mediating transactivation or transrepression, respectively). For monomeric tethering, ligand-bound monomeric $GR\alpha$ bind directly to a secondary transcription factor to either positively or negatively regulate downstream gene expression (transactivation or transrepression, respectively). For cell membrane receptor signalling, glucocorticoids bind to cell membrane-bound receptors and mediate transmembrane activity resulting in non-genomic signalling. For chaperone protein signalling, the disassociation of chaperone proteins from the $GR\alpha$ on the binding of ligand liberates the chaperone proteins such they can influence changes in intracellular signalling pathways mediated by unbound chaperone proteins secondary to their disassociation from ligand bound $GR\alpha$. For PI3K competition, ligand bound $GR\alpha$ can sequester PI3K modifying preventing its ability to activate AKT and regulate downstream AKT signalling the ability of PI3K to influence AKT signalling. [Au: Could you please clarify what you mean by this last sentence?].

[Au: Does “RE” (following XY and $NKkB$) refer to “response elements”?]

[Au: You’ve also mentioned “competition for PI3K” in the figure - could you briefly mention this aspect in the figure legend?]

Figure 5: The deleterious actions of glucocorticoids in muscle and bone.

Comment [RH(oMaSR108): Mark. The figure for this implies that PI3K bound to GR can still signal. I don’t think this is the case. Can you make a note for artistic editor that GR binding blocks PI3K signalling (Figure 4)

Comment [MC109]: Hopefully done

Comment [MC110]: This is not correct. It should be NF-kappaB with kappa as a symbol. It stands for nuclear factor kappa B.

Comment [MC111]: Yes RE is response element.

Comment [MC112]: Hopefully done

In muscle, glucocorticoids induce catabolic (E3 ligase and FOXO1) and anti-anabolic (Myostatin and DDIT4) signalling pathways and suppress anabolic signalling pathways (IGF-1, S6K1, 4E-BP, PI3K, AKT and mTOR), resulting in muscle wasting. In osteocytes, glucocorticoids directly induce the release of the anti-anabolic Wnt inhibitor sclerostin and induce osteocyte autophagy and apoptosis through increased BIM, ER stress and ATG7 signalling. Glucocorticoids suppress bone formation by inhibiting factors that regulate osteoblast differentiation and proliferation (Wnt, BMP, TGF β [Au: OK?], DKK1, sex steroids, AP-1) and inducing factors that induce osteoblast apoptosis and autophagy (PyK2, JNK, Bim, E4BP4, ER stress). Osteoclastic Bone resorption is directly upregulated by glucocorticoids via osteoclasts [Au: by glucocorticoids?] through the direct suppression of OPG in combination with- induction of proteolytic enzymes in osteoclasts such as collagenase 3. Glucocorticoids can also have secondary effects on bone metabolism (green boxes). Briefly, glucocorticoids directly suppress lower OPG secondary to the reduction in mature osteoblasts and osteocyte numbers, whilst the reduction in muscle mass results in reduced loading and mechanosensing by osteoclasts, which further suppresses OPG production by these cells. . suppression of osteoblast differentiation and maturation. [Au: If they directly suppress OPG, isn't this a primary (rather than secondary) mechanism that should instead be mentioned above?] in osteocytes and osteoblasts, as well as indirectly suppress OPG in response to decreased mechanosensing in patients with muscle wasting [Au: Could you explain this mechanism a little more (I'm not sure I understand the link between muscle mass, mechanosensing and OPG production) - perhaps you could expand on this slightly for clarity?]. This occurs in conjunction with the direct induction of RANKL in osteoblasts. Together these shift the OPG to RANKL ratio in favour of increased osteoclast maturation and activation and increased bone resorption. Therapeutic interventions are able to prevent bone loss through their targeting of either anabolic or catabolic bone metabolism in osteoblasts and osteoclasts. The parathyroid hormone analogue tTeriparatide promotes anabolic bone formation in osteoclasts, promoting their differentiation and survival. Anti-catabolic agents such as bBisphosphonates directly promote cell death and apoptosis in osteoclasts, whilst dDenosumab blocks RANKL signalling in osteoclasts, preventing their maturation and activation.

[Au: You also include therapeutic interventions in this figure (bisphosphates, denosumab and teriparatide). Could you mention these aspects in the figure legend?]

Table 1: Effects of therapeutic glucocorticoids on different cell types [Au: Shortened title OK?]

Cell type	Effect of therapeutic glucocorticoids on cellular responses	References [Au: I've created row for each effect as we no longer have bullet points in our tables (and so this seemed to be the best way to display this information). However, I wasn't sure which reference referred to which effect - could you

Comment [MC113]: yes

Comment [RH(oMaSR114): addressed

Comment [RH(oMaSR115): this has been expanded

Comment [RH(oMaSR116): These have been included

Comment [MC117]: yes ok

		please move each to the correct row (making sure there is at least one reference for each?)
Adaptive immune cells		
T helper cells	Decreased Th1 and Th17 differentiation and cytokine production	Liberman AC et al. Cytokine Growth Factor Rev. (2007) ⁸² Franchimont D et al. J Immunol. (2000) ⁸⁴
	Increase apoptosis	Reichardt HM et al. Cell. (1998) ³⁷
	Decrease T cell signalling	Franchimont D et al. J Immunol. (2000) ⁸⁴
	Increased T _H 2 differentiation and cytokine production	Franchimont D et al. J Immunol. (2000) ⁸⁴ Ramírez F et al. J Immunol. (1996) ⁸³
	Increased T _H 2 effects	
Cytotoxic T cells	Decreased cytokine production	Schleimer RP et al. J Immunol. (1984) ⁸⁶
	Increased apoptosis	Migliorati G et al. Pharmacol. Res. (1992) ⁸⁵
	Decreased T cell signalling	Schleimer RP et al. J Immunol. (1984) ⁸⁶
	Decreased cytotoxic capacity	Schleimer RP et al. J Immunol. (1984) ⁸⁶
B cells	Decreased B cell receptor signalling	Cupps TR et al. J Clin Invest. (1985) ⁸⁸ Franco LM et al. J Exp Med. (2019) ⁴⁴
	Increased apoptosis	Lill-Elghanian D et al. Exp Biol Med. (2002) ⁸⁷
	Decreased TLR7 and BCR signalling	Franco LM et al. J Exp Med. (2019) ⁴⁴
	Upregulation of BLIMP1 and IL-10	Franco LM et al. J Exp Med. (2019) ⁴⁴
Innate immune cells		
Mast cells	Decreased Toll like receptor signalling	Zhou J et al. Allergy. (2008) ⁸⁹
	Increased histamine release	Zhou J et al. Allergy. (2008) ⁸⁹
Macrophages	Decreased pro-inflammatory cytokines	Franchimont D. Ann N Y Acad Sci. (2004) ⁹² Zhou JY et al. Br J Surg. (2010) ⁹³
	Increased pro-resolution cytokines	Barczyk K et al. Blood. (2010) ⁹⁰ Franchimont D. Ann N Y Acad Sci. (2004) ⁹²
	Increased efferocytosis phagocytosis	McColl A et al. J Immunol. (2009) ⁹¹ Zhou JY et al. Br J Surg. (2010) ⁹³
	Increased M2 polarisation	Barczyk K et al. Blood. (2010) ⁹⁰
	Decreased Toll like receptor signalling	Franchimont D. Ann N Y Acad Sci. (2004) ⁹²
Neutrophils	Increased production	Cavalcanti DM et al. Pharmacol. (2007) ⁹⁵
	Decreased extravasation	Filep, JG et al. Circulation (1997) ⁹⁴ Cavalcanti DM et al. Pharmacol. (2007) ⁹⁵
Basophils or Eosinophils	Decreased Toll like receptor signalling	Mogensen TH et al. Infect Immun. (2008) ⁹⁸
	Increased apoptosis	Sivertson KL et al. Cell Immunol. (2007) ⁹⁷
	Increased expression of CXCR4 and migration to the spleen, bone marrow and lymph	Khoury P et al. Allergy. (2018) ⁹⁶
Resident mesenchymal cells		
Osteoblasts or osteocytes	Decreased differentiation	Rauch A et al. Cell (2010) ³⁹
	Increased apoptosis	Chen F et al. Calcif Tissue Int. (2014) ⁹⁹
	Increased RANKL	Swanson C et al. Endocrinology (2006) ¹⁰⁰

Comment [RH(oMaSR118): I have amended the headings and deleted one column to address the point on T cell function

		Humphrey EL et al. Bone. (2006) ¹⁰¹
	Decreased OPG	Swanson C et al. Endocrinology (2006) ¹⁰⁰ Humphrey EL et al. Bone. (2006) ¹⁰¹
Chondrocytes	Increased MMP activity	Huang Y et al. J Steroid Biochem Mol Biol. (2018) ¹⁰²
	Decreased GAC production	Huang Y et al. J Steroid Biochem Mol Biol. (2018) ¹⁰²
Myoblasts and fused Myotubes	Increased proteolysis	Braun TP et al. Front Physiol. (2015) ¹⁰³
[Au: What cells are you referring to?]	Increased autophagy	Troncoso R et al. Cell Cycle. (2014) ¹⁰⁴
Stromal fibroblasts	Decreased cytokine and chemokine production	Hardy RS et al, Arth Res Ther (2006) ¹⁰⁵
	Decreased invasiveness	Durmus M et al. Anesth Analg. (2003) ¹⁰⁶
	Decreased lymphocyte adhesion	Durmus M et al. Anesth Analg. (2003) ¹⁰⁶
	Decreased wound healing	Durmus M et al. Anesth Analg. (2003) ¹⁰⁶
Cells linking innate & adaptive immunity innate/adaptive link immune cells [Au: What do you mean by "adaptive link immune cells"?]		
Natural killer cells	Increased activation	Pitzalis C et al. J Immunol. (1997) ¹⁰⁷ Pitzalis C et al. Ann N Y Acad Sci. (2002) ¹⁰⁸
Dendritic cells	Decreased cytokine production	Cao Y et al. Blood. (2013) ²⁸
	Decreased maturation	Elftman MD et al. Immunology. (2007) ¹⁰⁹ Cao Y et al. Blood. (2013) ²⁸
	Increased apoptosis	Cao Y et al. Blood. (2013) ²⁸
	Decreased antigen presentation	Elftman MD et al. Immunology. (2007) ¹⁰⁹

Comment [RH(oMaSR119): Hopefully this clarifies. Blasts fuse to form multinucleate myotubes (muscle fibres)

Comment [RH(oMaSR120): Clarified

Table 2: Effects of therapeutic glucocorticoids on mouse models of inflammatory arthritis

[Au: Shortened title OK?]

Comment [MC121]: ok

Study	Inflammatory mouse model [Au: OK?]	Transgenic mouse	Treatment with dexamethasone investigated?	Inflammatory outcome
Koenen et al. Ann Rheum Dis, 2018 ⁴⁹	STIA	Haematopoietic glucocorticoid receptor deletion	Yes	Normal response to glucocorticoid [Au: OK?]
		Stromal glucocorticoid receptor deletion	Yes	Resistant to glucocorticoid [Au: OK?]
Baschant et al. PNAS, 2011 ⁴⁸	AIA	Macrophage glucocorticoid receptor deletion	Yes	Normal response to glucocorticoid
		Dendritic cell	Yes	Normal

Comment [MC122]: yes ok

Comment [MC123]: yes

Comment [MC124]: yes

		GR deletion		response to glucocorticoid
		B cell glucocorticoid receptor deletion	Yes	Normal response to glucocorticoid
		T cell glucocorticoid receptor deletion	Yes	Resistant to glucocorticoids
Tu et al. FASEB, 2018 ⁵¹	STIA	Chondrocyte blockade of glucocorticoid	No	Exaggerated inflammation and joint destruction [Au: OK?]
	AIA	Chondrocyte blockade of glucocorticoid	No	Exaggerated inflammation and joint destruction [Au: OK?]
Buttgereit et al. Arthritis Rheum, 2009 ⁵²	STIA	Osteoblast blockade of glucocorticoid signalling	No	Attenuated inflammation and joint destruction [Au: OK?]
Hardy et al. J Autoimm, 2018 ¹²	TNF-transgenic model of arthritis [Au: OK?]	Global blockade of 11 β -HSD1 glucocorticoid activation	No	Exaggerated inflammation and joint destruction [Au: OK?]
		Stromal blockade of 11 β -HSD1 glucocorticoid activation	No	Attenuated inflammation and joint destruction [Au: OK?]
Coutinho et al. Endocrinology, 2012 ¹³	STIA	Global blockade of 11 β -HSD1 glucocorticoid activation	No	Exaggerated inflammation and joint destruction

Comment [MC125]: yes

Comment [MC126]: yes

Comment [MC127]: yes ok

Comment [MC128]: yes ok

Comment [MC129]: yes ok

Comment [MC130]: yes ok

1014 AIA, antigen-induced arthritis; STIA, Serum transfer induced arthritis

1015 **Table of contents blurb**

1016 Glucocorticoids are anti-inflammatory therapies commonly used in rheumatology but have
 1017 wide-ranging adverse effects. Understanding the pharmacokinetic properties and

Hardy et al.,

Therapeutic Glucocorticoids

1018 mechanisms of action of glucocorticoids could inform in the development of novel therapies
1019 with fewer adverse effects. [Au: OK?]

Comment [MC131]: yes